Patient-derived xenografts: A relevant preclinical model for drug development

Luca Pompili, Manuela Porru, Carla Caruso, Annamaria Biroccio, Carlo Leonetti

Research output: Contribution to journalReview article

Abstract

Identifying appropriate preclinical cancer models remains a major challenge in increasing the efficiency of drug development. A potential strategy to improve patient outcomes could be selecting the 'right' treatment in preclinical studies performed in patient-derived xenografts (PDXs) obtained by direct implants of surgically resected tumours in mice. These models maintain morphological similarities and recapitulate molecular profiling of the original tumours, thus representing a useful tool in evaluating anticancer drug response. In this review, we will present the state-of-art use of PDXs as a reliable strategy to predict clinical findings. The main advantages and limitations will also be discussed.

Original languageEnglish
Article number189
JournalJournal of Experimental and Clinical Cancer Research
Volume35
Issue number1
DOIs
Publication statusPublished - Dec 5 2016

Keywords

  • Immunosuppressed mice
  • Orthotopic
  • Patient-derived-xenografts
  • Predictive value
  • Subcutaneous
  • Tumor heterogeneity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Patient-derived xenografts: A relevant preclinical model for drug development'. Together they form a unique fingerprint.

  • Cite this